Wolfram syndrome

Wolfram syndrome, also known as DIDMOAD syndrome (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness), is a rare, progressive neurodegenerative disorder that affects multiple organ systems. It was first described by Wolfram and Wagener in 1938. The condition is primarily caused by mutations in the WFS1 gene (Wolfram syndrome type 1) or, less commonly, the WFS2/CISD2 gene (Wolfram syndrome type 2). These genes encode proteins involved in endoplasmic reticulum function and calcium homeostasis, and their dysfunction leads to cellular stress and progressive cell death in multiple tissues. The hallmark features of Wolfram syndrome typically present in a sequential pattern during childhood and adolescence. Insulin-dependent diabetes mellitus is usually the first manifestation, often appearing around age 6, followed by bilateral optic atrophy leading to progressive vision loss, typically by age 11. Central diabetes insipidus and sensorineural hearing loss commonly develop during the second decade of life. Additional features may include urinary tract abnormalities (such as hydroureter, hydronephrosis, and neurogenic bladder), neurological complications (including cerebellar ataxia, peripheral neuropathy, and cognitive decline), and psychiatric manifestations such as depression and anxiety. Some patients also develop autonomic dysfunction and hypogonadism. There is currently no cure for Wolfram syndrome, and management is primarily supportive and symptomatic. Treatment includes insulin therapy for diabetes mellitus, desmopressin for diabetes insipidus, hearing aids or cochlear implants for deafness, and visual aids for optic atrophy. Regular monitoring by a multidisciplinary team including endocrinologists, ophthalmologists, neurologists, audiologists, and urologists is essential. Investigational therapies targeting endoplasmic reticulum stress, such as sodium valproate and GLP-1 receptor agonists, are being studied in clinical trials. The prognosis is variable, but the condition is progressive, with median life expectancy historically reported around 30–40 years, often due to central respiratory failure from brainstem atrophy.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Wolfram syndrome